From a molecular perspective, accumulating evidence indicates that ovarian small-cell carcinomas, particularly the hypercalcemic type, almost universally carry deleterious SMARCA4 mutations, leading to their reclassification as malignant rhabdoid tumors within the same pathological spectrum (16–18). This evidence concerns the gene SMARCA4 and ovarian small cell carcinoma.